No fee unless we recover compensation for your family Text size 833-4-ASBESTOS (833-427-2378) Free Case Review

Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value

Our plain-English summary of Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value, by N. Shaker, D. Wu, A.M. Abid (Diagnostic Cytopathology, 2022).

You don't need the product names or old records. No fee unless we recover compensation for your family.

Call 833-4-ASBESTOS Request a review

The study

Abstract

Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy with a poor prognosis. Because of this tumor rarity and overlapping histologic features with other malignancy types, the histopathological findings and diagnostic immunohistochemical workup are essential in establishing the final diagnosis of MPMs. We aimed to review the diagnostic criteria, WHO tumor classification updates, and immunohistochemical staining markers diagnostic value to achieve an appropriate clinical diagnosis.

© 2022 The Authors. Diagnostic Cytopathology published by Wiley Periodicals LLC.

In plain English

This article was a short educational review, not an original study. The authors reviewed the cytology of malignant pleural mesothelioma: diagnostic criteria, the 2015 WHO classification and a forthcoming update, and staining markers used to confirm the diagnosis. They opened with an educational case of a 63-year-old man who had worked in a shipyard for 30 years and was exposed to visible clouds of asbestos dust. Summarizing other published work, the review listed features that point to malignant cells in pleural fluid, such as numerous large cell clusters and necrosis. It said that cell groups with knobby borders help tell mesothelioma apart from adenocarcinoma. It described three main subtypes: epithelioid, sarcomatoid and biphasic. It stated that loss of the BAP1 marker is seen in a substantial subset of malignant mesotheliomas but not in benign mesothelial growths, and that the usefulness of the D2-40 marker is yet to be evaluated. Citing another source, it said the disease is linked to asbestos exposure in 54% to 90% of patients. The authors concluded that a combined panel of staining markers seems essential for accurate diagnosis.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

  • Design: Narrative educational review ("Timely Review") built around an illustrative educational case; no new data were collected or analyzed
  • Who was studied: No study population. The review included one educational case: a 63-year-old male former carpenter with right-sided pleural effusion and pleural thickening. The article gives no place or date for the case.
  • Exposure: In the educational case, 30 years of shipyard work (construction, repair and demolition of vessels), often below deck, with exposure to visible clouds of asbestos dust. No fiber type was specified for the case. The review described asbestos in general terms as serpentine and amphibole.
  • Main results:
    • Citing earlier cytology literature, the review listed key features for detecting malignant cells in pleural fluid: a "second population" of cells, numerous large clusters, necrosis, and lacunae.
    • The review stated that mesothelioma cells can be told apart from adenocarcinoma by features including cell groups with knobby borders ("morulae").
    • The review described the 2015 WHO classification of pleural mesothelioma as having three major subtypes: epithelioid, sarcomatoid and biphasic.
    • The review stated that the major change in the forthcoming WHO classification is the inclusion of mesothelioma in situ as a diagnostic category.
    • Citing another source, the review stated that BAP1 staining is lost in a substantial subset of malignant mesotheliomas but retained in benign mesothelial proliferations.
    • The review stated that the diagnostic usefulness of the D2-40 marker is yet to be evaluated and that it should be interpreted with caution.
    • Citing another source, the review stated that malignant pleural mesothelioma is linked to asbestos exposure in 54% to 90% of patients.
  • The authors' conclusion: The authors concluded that a combined immunohistochemical staining panel with other markers seems to be essential to get accurate diagnostic results.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Medical terms in this study, explained in our Lexicon: Cytology, Pleural Mesothelioma, WHO Classification, Immunohistochemistry, Prognosis.

Browse more research in Diagnostic Cytopathology, or return to medical research.

How to cite it

Cite the study

N. Shaker, D. Wu, A.M. Abid. Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value. Diagnostic Cytopathology 2022;50(11):532-537. doi:10.1002/dc.25053. PMID: 36069384.

Cite our summary

“Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value.” AsbestosClaims.Law Library. https://asbestosclaims.law/library/research/cytology-of-malignant-pleural-mesothelioma-diagnostic-criteria-who.

ACL Doc numbers and their short links never change. See how to cite the Library.

Talk with an asbestos lawyer

Start with what you remember, and we'll take it from there.

This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.